| Non-viral vectors for RNA delivery Y Yan, XY Liu, A Lu, XY Wang, LX Jiang, JC Wang Journal of Controlled Release 342, 241-279, 2022 | 221 | 2022 |
| A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives Y Shi, A Lu, X Wang, Z Belhadj, J Wang, Q Zhang Acta Pharmaceutica Sinica B 11 (8), 2396-2415, 2021 | 111 | 2021 |
| Base-Mediated [3+ 4]-Cycloaddition of Anthranils with Azaoxyallyl Cations: A New Approach to Multisubstituted Benzodiazepines J Feng, M Zhou, X Lin, A Lu, X Zhang, M Zhao Organic letters 21 (16), 6245-6248, 2019 | 61 | 2019 |
| Nanomedicines reprogram synovial macrophages by scavenging nitric oxide and silencing CA9 in progressive osteoarthritis Y Yan, A Lu, Y Dou, Z Zhang, XY Wang, L Zhai, LY Ai, MZ Du, LX Jiang, ... Advanced Science 10 (11), 2207490, 2023 | 50 | 2023 |
| Ionic liquids: promising approach for oral drug delivery L Jiang, Y Sun, A Lu, X Wang, Y Shi Pharmaceutical Research 39 (10), 2353-2365, 2022 | 19 | 2022 |
| Lipid Nanoparticular Codelivery System for Enhanced Antitumor Effects by Ferroptosis–Apoptosis Synergistic with Programmed Cell Death-Ligand 1 Downregulation W Cao, X Zhang, Y Feng, R Li, A Lu, Z Li, F Yu, L Sun, J Wang, Z Wang, ... ACS nano, 2024 | 11 | 2024 |
| Local sustained release of PD-1 monoclonal antibody and lenvatinib by thermo-sensitive hydrogel for improving tumor immunotherapy L Zhai, Y Shi, Y Yan, A Lu, X Liu, L Lei, Y Sun, L Jiang, X Wang, H Qian, ... Chinese Chemical Letters 34 (8), 108104, 2023 | 9 | 2023 |
| Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment W Cao, X Zhang, R Li, Z Li, A Lu, F Yu, L Sun, J Wang, Z Wang, H He Journal of Controlled Release 368, 52-65, 2024 | 8 | 2024 |
| Nanomedicines promote cartilage regeneration in osteoarthritis by synergistically enhancing chondrogenesis of mesenchymal stem cells and regulating inflammatory environment SH Cui, Y Yan, A Lu, Y Dou, ZW Li, ZH Zhu, MZ Du, YF Zhu, X Chen, ... ACS nano 18 (11), 8125-8142, 2024 | 8 | 2024 |
| Design and development of ICCA as a dual inhibitor of GPIIb/IIIa and P-selectin receptors H Chen, A Lu, X Zhang, L Gui, Y Wang, J Wu, H Feng, S Peng, M Zhao Drug Design, Development and Therapy, 2097-2110, 2018 | 8 | 2018 |
| 小干扰 RNA 的非病毒载体: 从实验室走向临床 卢安， 王向宇， 闫仪， 王坚成 药学进展 46 (4), 270-281, 2022 | 4 | 2022 |
| Natural endogenous material-based vehicles for delivery of macromolecular drugs LU An, DU Kang, W Meng, ZHU Zehang, LEI Lei, SHI Yujie Chinese Journal of Natural Medicines 22 (12), 1163-1176, 2024 | 1 | 2024 |
| 儿童口服液体药物制剂的技术难点及研发策略分析 陈鑫， 卢安， 王向宇， 王晓玲， 郑爱萍， 王坚成 药学学报 56 (1), 130-137, 2021 | 1 | 2021 |
| Enhanced Tumor Immunotherapy by Triple Amplification Effects of Nanomedicine on the STING Signaling Pathway in Dendritic Cells XY Wang, Y Yan, XR Guo, A Lu, LX Jiang, YJ Zhu, YJ Shi, XY Liu, ... Advanced Healthcare Materials, 2403143, 2025 | | 2025 |
| Double Braking Effects of Nanomedicine on Mitochondrial Permeability Transition Pore for Treating Idiopathic Pulmonary Fibrosis A Lu, Z Xu, Z Zhao, Y Yan, L Jiang, J Geng, H Jin, X Wang, X Liu, Y Zhu, ... Advanced Science, 2405406, 2024 | | 2024 |
| Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy A Lu, Y Guo, Y Yan, L Zhai, X Wang, W Cao, Z Li, Z Zhao, Y Shi, Y Zhu, ... Chinese Chemical Letters 35 (6), 108928, 2024 | | 2024 |
| 肿瘤微环境响应型的 RNA 药物递送系统的研究进展 卢安， 王向宇， 闫仪， 王坚成 药学学报 57 (1), 109-121, 2022 | | 2022 |
Yujie ShiPeking UniversityEmail verificata su bjmu.edu.cn